Ocular endpoints can pose challenges in otherwise well-managed clinical trials. IOP, BCVA, OCT, visual fields, and fundus imaging require trained ophthalmic personnel, calibrated equipment, consistent execution methodology, and participant access. When those elements vary across sites due to different assessors, equipment drift, inconsistent protocols, or participant travel barriers, data quality and protocol adherence are at risk.
That is where most clinical trial management solutions stop. They coordinate trials effectively but do not physically perform specialized ophthalmic endpoints. That execution gap, who actually performs the OCT scan, calibrates the tonometer, and brings the assessment to the participant, is where endpoint failures can begin.
20/20 Onsite fills that gap through specialized ophthalmic endpoint execution that integrates within CRO-led trial operations without replacing them.
Endpoint failures can occur even when trial management is strong. A well-coordinated trial with solid CRO oversight and effective CTMS tracking can still face execution risks if ocular endpoints are not performed consistently.
This risk becomes particularly pronounced with precision-dependent endpoints. Trial coordination may be excellent, but if execution varies across sites due to different assessors, inconsistent calibration, and fragmented training, data quality faces regulatory risk.
That is because trial management solutions coordinate and track trials, but do not physically perform ophthalmic endpoints. Specialized endpoint execution requires calibrated equipment, certified ophthalmic assessors, standardized methodology, and point-of-need delivery capabilities that most CROs and CTMS platforms are not designed to provide.
Clinical trial management solutions, whether CTMS software platforms or CRO-led trial coordination, handle critical functions: site selection, regulatory submissions, data management, protocol oversight, and trial coordination.
What they typically do not handle is the physical execution of specialized ophthalmic endpoints. That means:
This is the execution gap. CROs manage the trial. CTMS platforms track the data. But who actually performs the IOP measurement, captures the OCT scan, and executes the BCVA assessment with the precision and consistency these endpoints require?
That execution layer, the physical performance of ophthalmic endpoints, is what 20/20 Onsite provides.
Ophthalmic endpoints pose numerous challenges that call for specialized execution.
IOP, BCVA, and OCT endpoints require precision in both data collection and interpretation. These endpoints are highly variable, so it’s imperative that certified professionals perform them. Otherwise, they can become points of failure in the study.
The equipment required to perform these trial processes must be calibrated correctly. These are sophisticated imaging devices that must be run by certified assessors to offer reliable, high-quality clinical data. General management services aren’t equipped to perform these tasks, which means you could end up with unqualified assessors gathering and interpreting key data.
Clinical study management for ophthalmic endpoints must also consider participant burden. Retention is a concern for all clinical studies. Participants may struggle to keep up with site visits for data gathering, which could lead them to drop out of the study. Replacing them will slow the process and add to the overall financial burden.
Point-of-need execution strategies help reduce participant burden. This hybrid execution model enables participants to meet clinical trial requirements without requiring travel. They can visit sites in their own community, saving valuable time and money.
Relying solely on standard clinical trial management solutions can threaten the integrity of your study's physical execution. These management tools won’t provide the specialized ophthalmic endpoint execution required for data quality you can rely on.
When endpoints aren’t protected, your clinical studies can face a number of issues. One of these is protocol deviations resulting from inconsistent execution.
Protocol deviations can include:
Protocol complexity is usually to blame for these failures. Inadequate site training can also cause issues with everything from enrollment to electronic data capture.
Enrollment and retention are always challenges. One particularly serious concern is patients missing assessment visits. There may be strict timelines to follow in clinical studies, and participants who lack reliable transportation or must travel a significant distance can become weak points in the study.
This complication can worsen significantly if clinical trial management issues cause further delays. For instance, if there are data-quality issues, it will be necessary to repeat assessments, which further burdens participants and adds to delays and overall costs.
A lack of operational efficiency can translate to study-threatening costs. Timeline delays, including study start-up schedule issues, can cost a trial between $600,000 and $8 million per day.
Dropout expenses are also consequential. It costs about $6,533 to recruit a single study participant and an average of $19,533 to replace them. Needless to say, this kind of expense can put serious strain on a study.
20/20 Onsite complements existing trial infrastructure by focusing on what CROs and CTMS platforms typically don't: the physical execution of ophthalmic endpoints.
Our services integrate within CRO-led operations without replacing trial management functions. Our focus is endpoint execution: calibrated equipment, certified assessors, standardized methodology, point-of-need delivery, and single-call accountability for the ocular endpoint execution cycle.
This model complements trial management by strengthening the execution layer that most CROs and CTMS solutions do not own.
20/20 Onsite focuses on point-of-need delivery. We offer both mobile research sites and centralized options to provide the full support a study needs.
Your study teams can bring ocular assessments directly to patients rather than requiring them to come to you. This relieves participant burden while still meeting key regulatory requirements, as all equipment is properly calibrated, operated by qualified personnel, and aligned with protocol requirements.
Our single-call accountability is another factor that can help your research teams carry out the study. One partner will be responsible for every aspect of the endpoint execution, promising streamlined services and more reliable results. This kind of responsiveness can also prevent miscommunication issues that could derail the trial.
With the right field execution partner, you’ll get results you can count on. 20/20 Onsite streamlines physical processes across sites, reducing the dropout rate to 9% from the industry standard of 30%. We offer all of our services with a 98% accuracy for data submission.
When choosing clinical trial management software and other solutions, it’s essential to look for a partner who can provide the necessary support without duplicating existing functions.
Interoperability is equally vital. The services you receive shouldn’t require you to change multiple pieces of software, and decision-making should still be left to stakeholders and other trial leaders.
A complete overhaul of a trial can be expensive and may upset interested parties. The right clinical trial management solutions keep this from happening.
It is not enough to rely solely on a software solution or trial-management company. The specialized clinical operations team you hire to supplement your CTMS must grasp the specific issues liable to arise in ophthalmic trials and offer end-to-end field assistance.
When selecting your CTMS software, it is wise to pair it with an execution partner that handles nationwide deployment and point-of-need delivery. Both aspects are essential for patient recruitment and retention. A hybrid execution model makes it easier for participants to keep up with their visits.
Another of the most important metrics to consider when choosing a trial solutions company is whether it can offer the necessary execution control at the point of assessment. Automation is integral for certain endpoints, as is electronic data capture (EDC). At the same time, hands-on assessments should also be performed by certified professionals.
Pricing is also a factor, of course. Research your options before making a decision, and make sure you know exactly what will be included in the quoted rate.
If your trial requires ocular endpoints, a general CTMS isn’t enough. 20/20 Onsite fills the physical execution gaps your software cannot cover.
We’re a difference-maker in audits, regulatory compliance, and overall participant satisfaction. Our team supports ophthalmic assessments and endpoint execution across Phase I, II, and III trials, and can also offer mobile eye exams for any therapeutic-area study with an ocular endpoint.
Our services integrate easily with CRO-led operations. The goal is to minimize disruption to your existing trial, which is why we offer complementary services to address weak points and vulnerabilities.
An endpoint-execution risk assessment can help identify issues in your current trial management services. Planning a trial with ocular endpoints? Schedule an ocular endpoint execution risk assessment with 20/20 Onsite.